Elvitegravir

CAT#: H314218

CAS#:

Description: Elvitegravir, also known as GS-9137 ans EVG, is an integrase inhibitor used to treat HIV infection. The drug gained approval by the U.S. Food and Drug Administration on August 27, 2012 for use in adult patients starting HIV treatment for the first time as part of the fixed dose combination known as Stribild.

img

Synthetic Routes

Elvitegravir - Synthetic Route 1

Elvitegravir route01

Synthetic reference

Elvitegravir - Synthetic Route 2

Elvitegravir route02

Synthetic reference

Elvitegravir - Synthetic Route 3

Elvitegravir route03

Synthetic reference

Elvitegravir - Synthetic Route 4

Elvitegravir route04

Synthetic reference

Elvitegravir - Synthetic Route 5

Elvitegravir route05

Synthetic reference

Elvitegravir - Synthetic Route 6

Elvitegravir route06

Synthetic reference

Elvitegravir - Synthetic Route 7

Elvitegravir route07

Synthetic reference

Elvitegravir - Synthetic Route 8

Elvitegravir route08

Synthetic reference

Elvitegravir - Synthetic Route 9

Elvitegravir route09

Synthetic reference

Elvitegravir - Synthetic Route 10

Elvitegravir route010

Synthetic reference

Elvitegravir - Synthetic Route 11

Elvitegravir route011

Synthetic reference

Ma, Shuai; Zhao, Jun; Du, Weihong; Cao, Shenghua. Synthesis of elvitegravir. Zhongguo Yiyao Gongye Zazhi. Sichuan Industrial Institute of Antibiotics. China National Pharmaceutical Group Co. Chengdu, Sichuan Province, Peop. Rep. China 610052. Volume 45. Issue 1. Pages 5-8. 2014.